Bisphosphonates in the treatment of skeletal metastases

被引:30
作者
Conte, P
Coleman, R
机构
[1] Univ Modena & Reggio Emilia, Dept Haematol & Oncol, Modena, Italy
[2] Weston Pk Hosp, Canc Res Ctr, Yorkshire Acad Unit Clin Oncol, Sheffield, S Yorkshire, England
关键词
D O I
10.1053/j.seminoncol.2004.07.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:59 / 63
页数:5
相关论文
共 46 条
  • [1] Extended safety profile of oral clodronate after long-term use in primary breast cancer patients
    Atula, S
    Powles, T
    Paterson, A
    McCloskey, E
    Nevalainen, J
    Kanis, J
    [J]. DRUG SAFETY, 2003, 26 (09) : 661 - 671
  • [2] Dosing regimens and main adverse events of bisphosphonates
    Body, JJ
    [J]. SEMINARS IN ONCOLOGY, 2001, 28 (04) : 49 - 53
  • [3] Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies
    Body, JJ
    Diel, IJ
    Lichinitzer, M
    Lazarev, A
    Pecherstorfer, M
    Bell, R
    Tripathy, D
    Bergstronn, B
    [J]. BRITISH JOURNAL OF CANCER, 2004, 90 (06) : 1133 - 1137
  • [4] Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases
    Body, JJ
    Diel, IJ
    Lichinitser, MR
    Kreuser, ED
    Dornoff, W
    Gorbunova, VA
    Budde, M
    Bergström, B
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (09) : 1399 - 1405
  • [5] A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease
    Castel, LD
    Bajwa, K
    Markle, JP
    Timbie, JW
    Zacker, C
    Schulman, KA
    [J]. SUPPORTIVE CARE IN CANCER, 2001, 9 (07) : 545 - 551
  • [6] Coleman R E, 2000, Oncologist, V5, P463, DOI 10.1634/theoncologist.5-6-463
  • [7] Metastatic bone disease: clinical features, pathophysiology and treatment strategies
    Coleman, RE
    [J]. CANCER TREATMENT REVIEWS, 2001, 27 (03) : 165 - 176
  • [8] Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298
    Coxon, FP
    Helfrich, MH
    Van't Hof, R
    Sebti, S
    Ralston, SH
    Hamilton, A
    Rogers, MJ
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (08) : 1467 - 1476
  • [9] Delea T, 2004, BONE, V34, pS86
  • [10] Diel I J, 2000, Clin Breast Cancer, V1, P43, DOI 10.3816/CBC.2000.n.003